Chemotherapy in neoplastic meningitis

Area of Science:

• Neuro-oncology
• Cancer Metastasis
• Cerebrospinal Fluid (CSF) Malignancy

Background:

• Neoplastic meningitis (NM) involves cancer cell spread within the cerebrospinal fluid (CSF), often a late-stage complication of solid tumors or lymphoproliferative diseases.
• Current therapeutic goals for NM are primarily palliative, emphasizing risk stratification to identify candidates for aggressive treatments like radiation and chemotherapy.
• The diffuse nature of NM throughout the subarachnoid space presents unique treatment challenges.

Purpose of the Study:

• To review and summarize current intrathecal and systemic chemotherapeutic strategies for managing neoplastic meningitis (NM).
• To discuss the efficacy and associated toxicities of various chemotherapy options in the context of NM treatment.
• To inform clinical decision-making regarding aggressive treatment approaches for eligible NM patients.

Main Methods:

• Comprehensive literature review of intrathecal and systemic chemotherapy for neoplastic meningitis.
• Analysis of treatment outcomes and toxicity profiles reported in relevant studies.
• Synthesis of information to evaluate current therapeutic options and controversies.

Main Results:

• Chemotherapy, both intrathecal and systemic, is considered a primary treatment modality for neoplastic meningitis (NM).
• Optimal chemotherapy regimens and administration routes remain a subject of ongoing clinical debate.
• Treatment decisions are influenced by patient risk assessment, malignancy type, and potential treatment-related toxicities.

Conclusions:

• Intrathecal and systemic chemotherapy represent key therapeutic options for neoplastic meningitis (NM).
• Further research is needed to establish universally optimal treatment protocols and manage NM-related toxicities effectively.
• Risk stratification is crucial for tailoring aggressive therapies to patients who may benefit most from interventions like chemotherapy and radiation.